Dubb, J. W. published the artcileTienilic acid: pharmacokinetics, salicylate interaction and creatinine secretion studies, Quality Control of 40180-04-9, the main research area is tienilate pharmacokinetics creatinine salicylate.
Oral doses of 250 mg tienilic acid (I) [40180-04-9] given to normal human volunteers provided peak blood levels of 10-11 μg/mL at 3-4 h after administration. Approx. 40% of the dose was recovered in 24 h, 30% as the parent compound, and 10% as the alc. and diacid metabolites. A 650 mg dose of acetylsalicylic acid [50-78-2] decreased the uricosuric effect of I by inhibiting uric acid secretion. Urine pH decreased with I administration. I inhibited salicylate excretion by either competition for tubular secretion or by increasing passive, pH dependent reabsorption. In normal subjects given a creatinine load, I did not inhibit creatinine [60-27-5] secretion.
Postgraduate Medical Journal, Supplement published new progress about tienilate pharmacokinetics creatinine salicylate. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Quality Control of 40180-04-9.
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem